Abstract: Inobrodib, also known as CCS1477, is a potent and specific small-molecule inhibitor targeting the bromodomains of the histone acetyltransferases p300 and CBP. By acting as an acetylated lysine competitive protein-protein interaction inhibitor, Inobrodib effectively suppresses the transcription of key oncogenes, notably MYC and the androgen receptor (AR). In the context of solid tumors, preclinical studies have demonstrated its robust efficacy in inhibiting cell proliferation and tumor growth in models of prostate cancer and NUT midline carcinoma, particularly when used in combination therapies. Currently, Inobrodib is undergoing Phase I/IIa clinical trials for advanced solid tumors, including metastatic castration-resistant prostate cancer, where early data indicate successful reduction of oncogenic biomarkers. This review synthesizes the pharmacological activity, molecular mechanisms, structural applications, limitations, and future perspectives of Inobrodib in solid tumor oncology based on recent literature.
1. Introduction
The histone acetyltransferases p300 (E1A-associated protein p300) and CBP (CREB binding protein) are critical epigenetic regulators that catalyze the acetylation of histone H3 at lysine 27 (H3K27). This epigenetic modification opens chromatin structures at gene promoters, enhancers, and super-enhancers, thereby facilitating the recruitment of transcriptional machinery and driving the expression of pivotal oncogenes [1]. The overexpression or hyperactivation of p300/CBP is implicated in tumor initiation, progression, and resistance to apoptosis across various cancer types [1]. Consequently, targeting p300/CBP has emerged as a promising therapeutic strategy. Inobrodib, widely referred to in the literature as CCS1477, is a highly selective p300/CBP bromodomain inhibitor that has recently transitioned from preclinical development into early-stage clinical trials for patients with advanced solid tumors and hematological malignancies [1].
2. Pharmacological Activity
Inobrodib (CCS1477) has demonstrated significant pharmacological activity against several solid tumor models in both in vitro and in vivo settings. In prostate cancer, CCS1477 suppresses cancer cell multiplication in cell culture and significantly inhibits tumor growth in mouse models [1]. It has been shown to repress androgen receptor (AR) expression and signaling in mice bearing castration-resistant prostate cancer patient-derived xenografts [1]. Furthermore, in NUT midline carcinoma cells, combination therapy utilizing CCS1477 alongside a BET bromodomain inhibitor synergistically reduces MYC gene expression and induces cancer cell apoptosis [1].
Clinically, CCS1477 is under investigation in Phase I/IIa clinical trials for patients with advanced solid tumors, including metastatic anti-androgen treatment-resistant prostate cancer. The trials specifically target tumors with biomarkers suggesting a high likelihood of treatment response, such as p300/CBP gene mutations, ARID1A mutations, or androgen receptor gene rearrangements and amplifications [1]. Early clinical data reveal that CCS1477 successfully reduces the expression of MYC and the proliferation marker Ki-67 in tumor tissues obtained from patients with metastatic castration-resistant prostate cancer [1].
3. Molecular Mechanism of Action
The molecular mechanism of Inobrodib (CCS1477) centers on its function as a specific and potent acetylated lysine competitive inhibitor of the CBP/p300 bromodomain protein-protein interaction [1]. The compound exhibits high binding affinity, with dissociation constant ($K_D$) values of 1.3 nM for p300 and 1.7 nM for CBP [1]. By binding to these bromodomains, CCS1477 prevents p300/CBP from interacting with acetylated histones and other transcriptional regulators at enhancer and super-enhancer regions.
This blockade results in a reduction of histone H3K27 acetylation at oncogene loci, which subsequently represses the transcription and expression of critical oncogenic drivers. Mechanistically, CCS1477 has been shown to directly decrease the levels of MYC and the androgen receptor, as well as the expression of their downstream target genes both in vitro and in vivo [1]. By dismantling the enhancer-mediated transcriptional activation of these oncogenes, CCS1477 effectively halts cancer cell proliferation and promotes cell death [1].
4. Structure-Activity Relationship (SAR)
While detailed atom-by-atom structure-activity relationship (SAR) mapping of CCS1477 is not exhaustively detailed in the provided text, its structural properties as a potent bromodomain binder have been leveraged for advanced drug design. Specifically, CCS1477 has served as the parental small molecule for the development of proteolysis-targeting chimeras (PROTACs). By utilizing the p300/CBP binding moiety of CCS1477, researchers designed the PROTAC degrader QC-182 [1]. QC-182 effectively induces the ubiquitination and degradation of p300/CBP proteins (with a half-maximal degradation concentration, $DC_{50}$, of 93 nM) and has been shown to suppress hepatocellular carcinoma cell growth and tumor progression in murine models more effectively than its parental inhibitor, CCS1477 [1].
5. Current Limitations
Despite the promising preclinical and early clinical data, several limitations remain regarding the therapeutic use of Inobrodib (CCS1477). First, while early clinical trial results are encouraging, the comprehensive safety profiles and potential treatment-emergent adverse events have not yet been fully disclosed [1]. Second, the mechanisms by which solid tumors might develop resistance or insensitivity to CCS1477 remain unknown, as there have been no reports detailing cancer cell resistance to p300/CBP inhibitors to date [1]. Finally, there is a broader limitation in the field regarding the lack of reported systematic toxicology studies—such as detailed blood, liver, and kidney toxicity analyses—in preclinical mouse models treated with p300/CBP inhibitors [1].
6. Future Perspectives
The future development of Inobrodib (CCS1477) and related p300/CBP targeted therapies in solid tumors will likely focus on combination strategies and advanced modalities. Because p300/CBP inhibitors show synergistic effects when combined with other agents, future clinical applications may involve pairing CCS1477 with standard-of-care chemotherapy, radiotherapy, or other targeted agents (such as BET bromodomain inhibitors) to maximize efficacy and mitigate potential toxicity by allowing for lower dosing [1].
Additionally, the successful design of the CCS1477-derived PROTAC QC-182 highlights a significant future direction: advancing PROTAC p300/CBP degraders into clinical trials, as they may offer superior potency and specificity compared to traditional occupancy-based inhibitors [1]. Future research must also prioritize the establishment of in vitro and in vivo models to study potential resistance mechanisms to CCS1477, alongside rigorous systematic toxicological and pharmacokinetic evaluations to ensure patient safety [1].
